Arcturus Therapeutics Holdings Inc.: directors' dealings · United States · SEC (Form 4)

About Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is a United States-based biopharmaceutical company headquartered in San Diego, California. Founded in 2013, the company has built its identity around messenger RNA and self-amplifying RNA medicines, evolving from a platform-development story into a commercial mRNA therapeutics and vaccines player. Its core technology stack centers on three assets: the proprietary LUNAR® lipid-mediated delivery system, the STARR® self-amplifying mRNA platform, and internal manufacturing capabilities for mRNA drug substance and drug product. For international equity investors, Arcturus fits squarely within the high-risk, high-upside biotech segment, where valuation is heavily driven by clinical execution, regulatory milestones, and partnership monetization rather than current scale. From a corporate history perspective, Arcturus was founded in 2013 and has maintained its principal executive offices in San Diego since inception. The company later underwent a redomiciliation to the United States in 2019, which helped simplify its legal and capital-markets profile as a U.S.-listed issuer. It is important to note that Arcturus is not a diversified pharmaceutical conglomerate; it is a specialist platform company whose competitive strength lies in its technology base and in the ability to translate that platform into partnered programs and proprietary product candidates. Arcturus’ main business lines are vaccines and therapeutics built on mRNA and self-amplifying mRNA. Key programs highlighted in recent company disclosures include ARCT-810, an mRNA therapeutic candidate for ornithine transcarbamylase deficiency, as well as vaccine programs, including self-amplifying COVID-19 vaccine initiatives commercialized through partners in Japan and advanced through collaboration-led pathways elsewhere. The company also emphasizes its manufacturing know-how, which can be strategically meaningful in an industry where process control, speed to clinic, and supply-chain reliability are critical differentiators. In competitive terms, Arcturus operates in a crowded field that includes major mRNA platform leaders and a range of specialty biotech companies pursuing rare diseases and vaccine opportunities. Its differentiation is based on a combination of proprietary delivery technology, a potentially dose-efficient sa-mRNA approach, and a partnership-oriented commercial model. Geographically, the company remains anchored in the United States, but its business footprint is international through development and commercialization relationships, particularly in Asia. Recent highlights include multiple 2025 and early 2026 corporate updates and financial disclosures, with continued focus on clinical progress for ARCT-810 and on the ongoing commercialization of self-amplifying mRNA vaccine assets via partners. For investors, Arcturus remains a science-driven growth story listed on the NASDAQ in the United States, with long-term optionality tied to pipeline execution, regulatory success, and broader adoption of its RNA platform.